The Scripps Research Institute (TSRI) is a nonprofit research institution whose philosophy emphasizes the creation of basic knowledge in the biosciences for its application in medicine, the pursuit of fundamental scientific advances through interdisciplinary programs and collaborations, and the education and training of researchers preparing to meet the scientific challenges of the future.
The Scripps Research Institute has two campuses: its headquarters in La Jolla, CA, and a new facility in Jupiter, FL.
La Jolla, CA
The La Jolla campus provides more than 1 million square feet of space on 35 acres of land (14.7 of which are owned by the institute) next to the Pacific Ocean. Located in close proximity to the University of California, San Diego, the campus is situated with easy access to San Diego's scientific community, which includes the Salk Institute for Biological Studies and Sanford-Burnham Medical Research Institute, as well as a concentration of some 300 biotechnology companies. For more information, see the California campus webpage.
The Jupiter, FL, campus consists of a 350,000-square-foot facility consisting of three buildings completed in early 2009. Adjacent to Florida Atlantic University and the future home of a branch of the Max Planck Institute, the new Scripps Florida campus is at the center of an emerging cluster of biotechnology and pharmaceutical firms. For more information, see the Florida campus webpage.
The more than 200 principal investigators at TSRI include many distinguished leaders in their fields, including two Nobel laureates and numerous members of the National Academy of Sciences (including its Institute of Medicine), American Academy of Arts and Sciences, and American Association for the Advancement of Science.
While academic divisions are de-emphasized across the institute to encourage collaboration, each faculty member belongs to one or more of the following departments:
A variety of academic centers and consortia also exist within the institute. For more information, see the Research and Faculty Overview.
In addition to the training of hundreds of postdoctoral fellows (see Postdoctoral Services), TSRI offers a distinguished graduate program in the biological and chemical sciences as well as outreach programs for high school and middle school students, teachers, and undergraduates.
Launched in 1989, TSRI’s Graduate Program is ranked among the top graduate schools in the country according to a number of metrics, including U.S. News & World Report. The publication now ranks TSRI’s Graduate Program seventh overall in chemistry, with a ranking of sixth in the specialty of organic chemistry and second in the specialty of biochemistry. The school is also rated ninth overall in the biological sciences. The school can now boast more than 500 accomplished alumni, who work in both academics and industry. For more information, see the Graduate Program webpage.
In addition, TSRI provides opportunities for younger students and their teachers to learn more about science and scientific careers. From internships to workshops, outreach activities aim to generate excitement about the power and potential of the biomedical sciences. For more information, see Outreach Programs.
Staff scientists: 66
Research associates: 357
Scientific and administrative support: 679
Adjunct, emeritus, visiting appointments: 286
TSRI graduate students: 200
Interns, trainees, etc: 304
California Total: 2,082
Staff scientists: 20
Research associates: 174
Scientific and administrative support: 230
Adjunct, emeritus, visiting appointments: 16
TSRI graduate students: 51
Interns, trainees, etc: 77
Florida Total: 622
(Updated quarterly: Figures as of October 22, 2015)
TSRI faculty are among the most prolific and entrepreneurial in the world, with:
Government-funded biomedical research in TSRI labs helps reveal the causes of disease. With this new knowledge, the institute then partners with industry— which provides the large investment needed (more than $1 billion per new drug) and specialized expertise needed for the development of new therapies.
TSRI’s corporate partners have included Pfizer, Bristol- Myers Squibb, Novartis, and Johnson & Johnson. The institute currently has more than 30 active partnerships.
Research at TSRI has led to:
Another 30+ drugs based on TSRI technology are in various stages of clinical development.
Grants and contracts provide funding for a significant portion of the institute's research activities. This revenue is derived primarily from the National Institutes of Health and other federal agencies. In addition, grantors include, among others, the American Cancer Society, the American Heart Association, the Cystic Fibrosis Foundation, the Leukemia & Lymphoma Society, and the Juvenile Diabetes Association.
Gifts from individuals and private foundations provide an important source of funding for TSRI. Private foundations that have provided support include the ALSAM Foundation, Lucille P. Markey Charitable Trust, W.M. Keck Foundation, Arnold and Mabel Beckman Foundation, Pew Charitable Trusts, the Ellison Medical Foundation, Bill & Melinda Gates Foundation, and Harold L. Dorris Foundation. For more information on making a contribution, see Donate Now.
The establishment of the Scripps Florida campus was made possible by a one-time $310 million appropriation of federal economic development funds and by the Florida State Legislature and by an economic package provided by Palm Beach County.
Financial statements (pdf) are available for the year ending: